The Use of Umbilical Cord Blood Nucleated Cells in the Treatment of Regressive Autism: A Case Report

Abstract

BACKGROUND: Interest in the issue of childhood autism has surged in the recent decades. At the same time, despite the significant progress achieved in understanding the etiological and pathogenetic aspects of the condition, effective ways to treat it have continued to elude us. Stem cell therapy appears to hold great promise in the treatment and rehabilitation of patients with both neurological diseases (cerebral palsy, hydrocephalus) and mental disorders (autism, schizophrenia).

METHODS: This article presents a case report describing the use of nucleated cord blood cells in a patient with regressive autism and resistance to standard therapies. The child’s condition was assessed before treatment and 6 and 12 months after.

RESULTS: Clinical observation, psychometric, and instrumental diagnostic methods led to a significant improvement in the child’s condition in the form of perception development, reduction of somatosensory disorders, normalization of emotional status, and a development of social and communication skills.

CONCLUSION: We assume that the result obtained may be associated with the normalization of the immunological status of our patient thanks to the cord blood cells therapy and consider it necessary to conduct further studies into the effectiveness of the method, taking the pathogenic mechanisms of autism into account.

Keywords

treatment / autism / cell therapy / children disorders / HUCBCs

References

[1] Iles A. Autism Spectrum Disorders. Prim Care. 2021 Sep;48(3):461-73. doi: 10.1016/j.pop.2021.04.003.

[2] Yin J, Schaaf CP. Autism genetics — an overview. PrenatDiagn. 2017;37(1):14-30. doi: 10.1002/pd.4942.

[3] Bhandari R, Paliwal JK, Kuhad A. Neuropsychopathology of autism spectrum disorder: complex interplay of genetic, epigenetic, and environmental factors. Adv Neurobiol. 2020;24:97–141. doi: 10.1007/978-3-030-30402-7_4.

[4] Thapar A, Rutter M. Genetic advances in autism. J Autism Dev Disord. 2021;51(12):4321–32. doi: 10.1007/s10803-020-04685-z.

[5] Goel R, Hong JS, Findling RL, Ji NY. An update on pharmacotherapy of autism spectrum disorder in children and adolescents. Int Rev Psychiatry. 2018;30(1):78–95. doi: 10.1080/09540261.2018.1458706.

[6] Persico AM, Ricciardello A, Cucinotta F. The psychopharmacology of autism spectrum disorder and Rett syndrome. Handbook of clinical neurology. 2019;165:391–414. doi: 10.1016/B978-0-444-64012-3.00024-1.

[7] Shmakova OP. Structural and dynamic features of early disability due to mental diseases. Pulse. 2020;22(10):62–7 (2020). doi: 10.26787/nydha-2686-6838-2020-22-10-62-67. Russian.

[8] Donegan JJ, Lodge DJ. Stem cells for improving the treatment of neurodevelopmental disorders. Stem Cells Dev. 2020;29(17):1118–30. doi: 10.1089/scd.2019.0265.

[9] Larijani B, ParhizkarRoudsari P, Hadavandkhani M, Alavi-Moghadam S, Rezaei-Tavirani M, Goodarzi P, Sayahpour FA, Mohamadi-Jahani F, Arjmand B. Stem cell-based models and therapies: a key approach into schizophrenia treatment. Cell Tissue Bank. 2021;22(2):207–23. doi: 10.1007/s10561-020-09888-3.

[10] Sun JM, Song AW, Case LE, Mikati MA, Gustafson KE, Simmons R, Goldstein R, Petry J, McLaughlin C, Waters-Pick B, Chen LW, Wease S, Blackwell B, Worley G, Troy J, Kurtzberg J. Effect of autologous cord blood infusion on motor function and brain connectivity in young children with cerebral palsy: a randomized, placebo-controlled trial. Stem Cells Trans Med. 2017;6(12):2071–8. doi: 10.1002/sctm.17-0102.

[11] Romanov YA, Tarakanov OP, Radaev SM, Dugina TN, Ryaskina SS, Darevskaya AN, Morozova YV, Khachatryan WA, Lebedev KE, Zotova NS, Burkova AS, Sukhikh GT, Smirnov VN. Human allogeneic AB0/Rh-identical umbilical cord blood cells in the treatment of juvenile patients with cerebral palsy. Cytotherapy. 2015;17(7):969–78. doi: 10.1016/j.jcyt.2015.02.010.

[12] Surugiu R, Olaru A, Hermann DM, Glavan D, Catalin B, Popa-Wagner A. Recent advances in mono- and combined stem cell therapies of stroke in animal models and humans. Int J Mol Sci. 2019;20(23):6029. doi: 10.3390/ijms20236029.

[13] Peng X, Song J, Li B, Zhu C, Wang X. Umbilical cord blood stem cell therapy in premature brain injury: Opportunities and challenges. J Neurosci Res. 2020;98(5):815-825. doi: 10.1002/jnr.24548.

[14] Wang SM, Lee CU, Lim HK. Stem cell therapies for Alzheimer’s disease: is it time? Curr Opin Psychiatry. 2019;32(2):105–16. doi: 10.1097/YCO.0000000000000478.

[15] Ternovoy S, Ustyuzhanin D, Morozova Y, Shariya M, Roldan-Valadez E, Smirnov V. Functional MRI evince the safety and efficacy of umbilical cord blood cells therapy in patients with schizophrenia. Schizophr Res. 2020;224:175–7. doi: 10.1016/j.schres.2020.09.028.

[16] Morozova YV, Radaev SM, Voronova EI, Emelina DA. Umbilical cord blood cells in the treatment of patients with schizophrenia in remission. Genes & Cells. 2021;16(1):75–81. doi: 10.23868/202104012. Russian.

[17] Lv YT, Zhang Y, Liu M, Qiuwaxi JN, Ashwood P, Cho SC, Huan Y, Ge RC, Chen XW, Wang ZJ, Kim BJ, Hu X. Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. J Transl Med. 2013;11:196. doi: 10.1186/1479-5876-11-196.

[18] Murias M, Major S, Compton S, Buttinger J, Sun JM, Kurtzberg J, Dawson G. Electrophysiological biomarkers predict clinical improvement in an ppen-label trial assessing efficacy of autologous umbilical cord blood for treatment of autism. Stem Cells Transl Med. 2018;7(11):783-791. doi: 10.1002/sctm.18-0090.

[19] Chez M, Lepage C, Parise C, Dang-Chu A, Hankins A, Carroll M. Safety and observations from a placebo-controlled, crossover study to assess use of autologous umbilical cord blood stem cells to improve symptoms in children with autism. Stem Cells Transl Med. 2018;7(4):333-341. doi: 10.1002/sctm.17-0042.

[20] Rubinstein P, Dobrila L, Rosenfield RE, Adamson JW, Migliaccio G, Migliaccio AR, Taylor PE, Stevens CE. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA. 1995 Oct 24;92(22):10119-22. doi: 10.1073/pnas.92.22.10119.

[21] Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother. 1996 Jun;5(3):213-26. doi: 10.1089/scd.1.1996.5.213.

[22] Pranke P, Hendrikx J, Alespeiti G, Nardi N, Rubinstein P, Visser J. Comparative quantification of umbilical cord blood CD34+ and CD34+ bright cells using the ProCount-BD and ISHAGE protocols. Braz J Med Biol Res. 2006;39(7):901–6. doi: 10.1590/s0100-879x2006000700008.

[23] Mayes SD. Brief report: checklist for autism spectrum disorder: most discriminating items for diagnosing autism. J Autism Dev Disord. 2018;48(3):935–9. doi: 10.1007/s10803-017-3401-0.

[24] Mahapatra S, Vyshedsky D, Martinez S, Kannel B, Braverman J, Edelson SM, Vyshedskiy A. Autism Treatment Evaluation Checklist (ATEC) norms: a “Growth Chart” for ATEC score changes as a function of age. Children (Basel). 2018;5(2):25. doi: 10.3390/children5020025.

[25] Panasyuk AY. [Adapted version of D. Wexler’s method (WISC)]. Moscow: Institute of Hygiene for Children and Adolescents of the Ministry of Health of the USSR; 1973. p. 80. Russian.

[26] Eggermont JJ. Auditory brainstem response. Handb Clin Neurol. 2019;160:451–64. doi: 10.1016/B978-0-444-64032-1.00030-8.

[27] Maric DM, Papic V, Radomir M, Stanojevic I, Sokolovac I, Milosavljevic K, Maric DL, Abazovic D. Autism treatment with stem cells: a case report. Eur Rev Med Pharmacol Sci. 2020;24(15):8075–80. doi: 10.26355/eurrev_202008_22491.

[28] Shroff G. Human embryonic stem cells in the treatment of autism: a case series. InnovClinNeurosci. 2017;14(3-4):12–6.

[29] Kobinia GS, Zaknun JJ, Pabinger C, Laky B. Case report: autologous bone marrow derived intrathecal stem cell transplant for autistic children - a report of four cases and literature review. Front Pediatr. 2021;9:620188. doi: 10.3389/fped.2021.620188.

[30] Okur SÇ, Erdoğan S, Demir CS, Günel G, Karaöz E. The effect of umbilical cord-derived mesenchymal stem cell transplantation in a patient with cerebral palsy: a case report. Int J Stem Cells. 2018;11(1):141–7. doi: 10.15283/ijsc17077.

[31] Zhang C, Huang L, Gu J, Zhou X. Therapy for cerebral palsy by human umbilical cord blood mesenchymal stem cells transplantation combined with basic rehabilitation treatment: a case report. Glob Pediatr Health. 2015;2:2333794X15574091. doi: 10.1177/2333794X15574091.

[32] Prosperi M, Guiducci L, Peroni DG, Narducci C, Gaggini M, Calderoni S, Tancredi R, Morales MA, Gastaldelli A, Muratori F, Santocchi E. Inflammatory biomarkers are correlated with some forms of regressive autism spectrum disorder. Brain Sci. 2019;9(12):366. doi: 10.3390/brainsci9120366.

[33] Liberman AC, Trias E, da Silva Chagas L, Trindade P, Dos Santos Pereira M, Refojo D, Hedin-Pereira C, Serfaty CA. Neuroimmune and inflammatory signals in complex disorders of the central nervous system. Neuroimmunomodulation. 2018;25(5-6):246–70. doi: 10.1159/000494761.

[34] Prem S, Millonig JH, DiCicco-Bloom E. Dysregulation of neurite outgrowth and cell migration in autism and other neurodevelopmental disorders. AdvNeurobiol. 2020;25:109–53. doi: 10.1007/978-3-030-45493-7_5.

[35] Donovan AP, Basson MA. The neuroanatomy of autism — a developmental perspective. J Anat. 2017;230(1):4–15. doi: 10.1111/joa.12542.

[36] Tamouza R, Fernell E, Eriksson MA, Anderlid BM, Manier C, Mariaselvam CM, Boukouaci W, Leboyer M, Gillberg C. HLA Polymorphism in regressive and non-regressive autism: a preliminary study. Autism Res. 2020;13(2):182-186. doi: 10.1002/aur.2217.

[37] Enstrom A, Onore C, Tarver A, Hertz-Picciotto I, Hansen R, Croen L, Van de Water J, Ashwood P. Peripheral blood leukocyte production of BDNF following mitogen stimulation in early onset and regressive autism. Am J BiochemBiotechnol. 2008;4(2):121–29. doi: 10.3844/ajbbsp.2008.121.129.

[38] Malek M, Ashraf-Ganjouei A, Moradi K, Bagheri S, Mohammadi MR, Akhondzadeh S. Prednisolone as adjunctive treatment to risperidone in children with regressive type of autism spectrum disorder: a randomized, placebo-controlled trial. ClinNeuropharmacol. 2020;43(2):39–45. doi: 10.1097/WNF.0000000000000382.

[39] Golla S, Sweeney JA. Corticosteroid therapy in regressive autism: preliminary findings from a retrospective study. BMC Med. 2014;12:79. doi: 10.1186/1741-7015-12-79.

[40] Jiang W, Xu J. Immune modulation by mesenchymal stem cells. Cell Prolif. 2020;53(1):e12712. doi: 10.1111/cpr.12712.

[41] Luque-Campos N, Contreras-López RA, Jose Paredes-Martínez M, Torres MJ, Bahraoui S, Wei M, Espinoza F, Djouad F, Elizondo-Vega RJ, Luz-Crawford P. Mesenchymal stem cells improve rheumatoid arthritis progression by controlling memory T cell response. Front Immunol. 2019;10:798. doi: 10.3389/fimmu.2019.00798.

[42] Damien P, Allan DS. Regenerative therapy and immune modulation using umbilical cord blood-derived cells. Biol Blood Marrow Transplant. 2015;21(9):1545–54. doi: 10.1016/j.bbmt.2015.05.022.

RIGHTS & PERMISSIONS

Morozova Y.V., Smirnov V.N., Makarov I.V., Emelina D.A.